Cognito Therapeutics raises $35M Series B extension
01/30/24, 1:49 AM
Location
cambridgeMoney raised
$35 million
Industry
health care
manufacturing
Investors
Wsgr, Starbloom, Iag Capital, Alzheimer’s Drug Discovery Foundation, Morningside, Founders X
Cognito Therapeutics raised a $35 million Series B extension round, bringing the total round to $108 million and its total funding to $128 million. The funding will be used to support the HOPE study for the treatment of Alzheimer’s, as well as the continued expansion and protection of its IP position in gamma frequency therapy. It will also be used to support its Ph2 studies in Multiple Sclerosis and Parkinson’s Disease.
Company Info
Location
55 cambridge pkwy
cambridge, massachusetts, united states
Additional Info
Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer’s disease.